Cargando…

Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active Treatment: An Observational Study at a Tertiary Cancer Centre in Lombardy, Italy

Background: The incidence and prognosis of SARS-CoV-2-positive cancer patients on active oncologic treatment remain unknown. Retrospective data from China reported higher incidence and poorer outcomes with respect to the general population. We aimed to describe the real-word incidence of SARS-CoV-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertuzzi, Alexia Francesca, Marrari, Andrea, Gennaro, Nicolò, Cariboni, Umberto, Ciccarelli, Michele, Giordano, Laura, Quagliuolo, Vittorio Lorenzo, Santoro, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564537/
https://www.ncbi.nlm.nih.gov/pubmed/32825295
http://dx.doi.org/10.3390/cancers12092352
_version_ 1783595737148293120
author Bertuzzi, Alexia Francesca
Marrari, Andrea
Gennaro, Nicolò
Cariboni, Umberto
Ciccarelli, Michele
Giordano, Laura
Quagliuolo, Vittorio Lorenzo
Santoro, Armando
author_facet Bertuzzi, Alexia Francesca
Marrari, Andrea
Gennaro, Nicolò
Cariboni, Umberto
Ciccarelli, Michele
Giordano, Laura
Quagliuolo, Vittorio Lorenzo
Santoro, Armando
author_sort Bertuzzi, Alexia Francesca
collection PubMed
description Background: The incidence and prognosis of SARS-CoV-2-positive cancer patients on active oncologic treatment remain unknown. Retrospective data from China reported higher incidence and poorer outcomes with respect to the general population. We aimed to describe the real-word incidence of SARS-CoV-2 in cancer patients and the impact of oncologic therapies on the infection. Materials & Methods: In this study, we analysed all consecutive cancer patients with solid tumours undergoing active intravenous treatment (chemotherapy, immunotherapy, targeted therapy, alone or in combination) between 21 February and 30 April 2020, in a high-volume cancer centre in Lombardy, Italy. We focused on SARS-CoV-2-positive patients, reporting on the clinical characteristics of the cancer and the infection. Results: We registered 17 SARS-CoV-2-positive patients among 1267 cancer patients on active treatment, resulting in an incidence of 1.3%. The median age was 69.5 years (range 43–79). Fourteen patients (82%) required hospitalisation for COVID-19 with a median in-hospital stay of 11.5 days (range 3–58). Fourteen of the seventeen (82%) were treated for locally advanced or metastatic disease. We could not demonstrate any correlation between SARS-CoV-2 infection and tumour or treatment type. The COVID-19-related fatality rate was 29% (5/17), which was higher than that of the general population cared for in our centre (20%). Conclusions: Active oncologic treatments do not represent a risk factor for SARS-CoV-2 infection in cancer patients. However, the prognosis of infected cancer patients appears to be worse compared with that of the non-oncologic population. Given the low number of SARS-CoV-2-positive cases and the uncertainties in risk factors that may have an impact on the prognosis, we advocate for the continuum of cancer care even during the current pandemic.
format Online
Article
Text
id pubmed-7564537
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75645372020-10-29 Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active Treatment: An Observational Study at a Tertiary Cancer Centre in Lombardy, Italy Bertuzzi, Alexia Francesca Marrari, Andrea Gennaro, Nicolò Cariboni, Umberto Ciccarelli, Michele Giordano, Laura Quagliuolo, Vittorio Lorenzo Santoro, Armando Cancers (Basel) Article Background: The incidence and prognosis of SARS-CoV-2-positive cancer patients on active oncologic treatment remain unknown. Retrospective data from China reported higher incidence and poorer outcomes with respect to the general population. We aimed to describe the real-word incidence of SARS-CoV-2 in cancer patients and the impact of oncologic therapies on the infection. Materials & Methods: In this study, we analysed all consecutive cancer patients with solid tumours undergoing active intravenous treatment (chemotherapy, immunotherapy, targeted therapy, alone or in combination) between 21 February and 30 April 2020, in a high-volume cancer centre in Lombardy, Italy. We focused on SARS-CoV-2-positive patients, reporting on the clinical characteristics of the cancer and the infection. Results: We registered 17 SARS-CoV-2-positive patients among 1267 cancer patients on active treatment, resulting in an incidence of 1.3%. The median age was 69.5 years (range 43–79). Fourteen patients (82%) required hospitalisation for COVID-19 with a median in-hospital stay of 11.5 days (range 3–58). Fourteen of the seventeen (82%) were treated for locally advanced or metastatic disease. We could not demonstrate any correlation between SARS-CoV-2 infection and tumour or treatment type. The COVID-19-related fatality rate was 29% (5/17), which was higher than that of the general population cared for in our centre (20%). Conclusions: Active oncologic treatments do not represent a risk factor for SARS-CoV-2 infection in cancer patients. However, the prognosis of infected cancer patients appears to be worse compared with that of the non-oncologic population. Given the low number of SARS-CoV-2-positive cases and the uncertainties in risk factors that may have an impact on the prognosis, we advocate for the continuum of cancer care even during the current pandemic. MDPI 2020-08-20 /pmc/articles/PMC7564537/ /pubmed/32825295 http://dx.doi.org/10.3390/cancers12092352 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bertuzzi, Alexia Francesca
Marrari, Andrea
Gennaro, Nicolò
Cariboni, Umberto
Ciccarelli, Michele
Giordano, Laura
Quagliuolo, Vittorio Lorenzo
Santoro, Armando
Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active Treatment: An Observational Study at a Tertiary Cancer Centre in Lombardy, Italy
title Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active Treatment: An Observational Study at a Tertiary Cancer Centre in Lombardy, Italy
title_full Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active Treatment: An Observational Study at a Tertiary Cancer Centre in Lombardy, Italy
title_fullStr Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active Treatment: An Observational Study at a Tertiary Cancer Centre in Lombardy, Italy
title_full_unstemmed Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active Treatment: An Observational Study at a Tertiary Cancer Centre in Lombardy, Italy
title_short Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active Treatment: An Observational Study at a Tertiary Cancer Centre in Lombardy, Italy
title_sort low incidence of sars-cov-2 in patients with solid tumours on active treatment: an observational study at a tertiary cancer centre in lombardy, italy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564537/
https://www.ncbi.nlm.nih.gov/pubmed/32825295
http://dx.doi.org/10.3390/cancers12092352
work_keys_str_mv AT bertuzzialexiafrancesca lowincidenceofsarscov2inpatientswithsolidtumoursonactivetreatmentanobservationalstudyatatertiarycancercentreinlombardyitaly
AT marrariandrea lowincidenceofsarscov2inpatientswithsolidtumoursonactivetreatmentanobservationalstudyatatertiarycancercentreinlombardyitaly
AT gennaronicolo lowincidenceofsarscov2inpatientswithsolidtumoursonactivetreatmentanobservationalstudyatatertiarycancercentreinlombardyitaly
AT cariboniumberto lowincidenceofsarscov2inpatientswithsolidtumoursonactivetreatmentanobservationalstudyatatertiarycancercentreinlombardyitaly
AT ciccarellimichele lowincidenceofsarscov2inpatientswithsolidtumoursonactivetreatmentanobservationalstudyatatertiarycancercentreinlombardyitaly
AT giordanolaura lowincidenceofsarscov2inpatientswithsolidtumoursonactivetreatmentanobservationalstudyatatertiarycancercentreinlombardyitaly
AT quagliuolovittoriolorenzo lowincidenceofsarscov2inpatientswithsolidtumoursonactivetreatmentanobservationalstudyatatertiarycancercentreinlombardyitaly
AT santoroarmando lowincidenceofsarscov2inpatientswithsolidtumoursonactivetreatmentanobservationalstudyatatertiarycancercentreinlombardyitaly